Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer

Clinical Cancer Research

Volumn 13, Issue 13, 2007, Pages 3883-3891

  Small, Eric J ^a,i   Sacks, Natalie ^b   Nemunaitis, John ^c   Urba, Walter J ^d   Dula, Eugene ^e   Centeno, Arthur S ^f   Nelson, William G ^g   Ando, Dale ^b   Howard, Catherine ^b   Borellini, Flavia ^b   Nguyen, Minh ^b   Hege, Kristen ^b   Simons, Jonathan W ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CELL GENESYS INC   (United States)

^c Mary Crowley Medical Research Center   (United States)

^d PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^e West Coast Clinical Research   (United States)

^f Urology San Antonio Research PA   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; BONE SCINTISCANNING; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL THERAPY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; DRUG MEGADOSE; FATIGUE; FLU LIKE SYNDROME; HUMAN; HUMAN TISSUE; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; RADIOLOGY; SAFETY; SKIN ULCER; SURVIVAL;

AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34447123763     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2937     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Tannock IF, deWit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
3. Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
4. Sanda MG, Ayyagari SR, Jaffee EM. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 1994;151:622-8.
5. Webster WS, Small EJ, Rini BI, Kwon ED. Prostate cancer immunology: biology, therapeutics, and challenges. J Clin Oncol 2005;23:8262-9.
6. Ando D. Gene therapy and molecular immunology unite to give new life to cancer immunotherapy. Mol Ther 2002;5:665-7.
7. Zhou G, Lu Z, McCadden JD, Levitsky HI, Marson AL. Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J Exp Med 2004;200:1581-92.
8. Warren TL, Weiner GJ. Uses of granulocyte-macrophage colony-stimulating factor in vaccine development. Curr Opin Hematol 2000;7:168-73.
9. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granuloctye-macrophage colony-stimulating factor stimulates potent, specific, and long lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993;90:3539-43.
10. Jaffee EM, Lazenby A, Meuer J, et al. Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials. J Immunother Emphasis Tumor Immunol 1995;18:1-9.
11. Jaffee E, Thomas M, Huang A, Hauda K, Levitsky H, Pardoll D. Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. J Immunother Emphasis Tumor Immunol 1996;19:176-83.
12. Simons JW, Mikhak B, Chang JF, et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999;59:5160-8.
13. Simons JW, Carducci MA, Mikhak B, et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer. Clin Cancer Res 2006;12:3394-401.
14. Jaffee EM, Hruban RH, Biedrzycki B, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001;19:145-56.
15. Thomas AM, Santarsiero LM, Lutz ER, et al. Mesothelin-specific CD8+ T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 2004;200:297-306.
16. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461-7. Erratum in: J Clin Oncol 2000;18:2644.
17. Noguchi M, Noda S. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer. J Urol 2001;166:1106-10.
18. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem 1975;250:4007-21.
19. Kaplan EI, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457.
20. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in menwith HRPC. J Clin Oncol 2003;21:1232-7.
21. Simons J, Higano C, Smith D, et al. Clinical and immunologic findings in a phase 2 study of a GM-CSF-secreting prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer (met HPRC) [Abstract 2517]. J Clin Oncol 2005;23:170.
22. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268-74.
23. van der Flier A, Sonnenberg A. Structural and functional aspects of filamins. Biochim Biophys Acta 2001;1538:99-117.
24. Takafuta T, Wu G, Murphy GF, Shapiro SS. Human β-filamin is a new protein that interacts with the cytoplasmic tail of glycoprotein Ibα. J Biol Chem 1998;273:17531-8.
25. Berry WR, Laszlo J, Cox E, et al. Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate. Cancer 1979;44:763-75.
26. Emrich LJ, Priore RL, Murphy GP, et al. Prognostic factors in patients with advanced stage prostate cancer. Cancer Res 1985;45:5173-9.
27. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer: the results of CALGB 9182. J Clin Oncol 1999;17:2506-13.
28. Soloway MS, Ishikawa S, van der Zwaag R, et al. Prognostic factors in patients with advanced prostate cancer. Urology 1989;33:53-6.
29. Gribben JG, Ryan DP, Boyajian R, et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res 2005;11:4430-6.
30. Antonia SJ, Mirza N, Fricke I, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006;12:878-87.
31. Arlen PM, Gulley JL, Parker C, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone inmetastatic androgen-independent prostate cancer. Clin Cancer Res 2006;12:1260-9.
32. Akimoto S, Akakura K, Shimazaki J. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer. Jpn J Clin Oncol 1996;26:157-63.
33. Noguchi M, Yahara J, Noda S. Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer. Urology 2003;61:993-8.